AntePC

Genetic risk test for of prostate cancer
Clinical recommendations based on your personal risk level for prevention and early detection
Recommended for men aged 40-70
Official healthcare service

Important information

E-mail *

Test results are connected to the e-mail you provide.

Post-test consultation

No

Yes (+50.00 €)

Additional test

AnteCRC (+30.00 €)

AnteCRC is a colorectal cancer genetic risk test. It is suitable for both sexes.

AnteMEL (+30.00 €)

AnteMEL is a melanoma genetic risk test. It is suitable for both sexes.

Service price:	195.00 €
Additional options total:
Order total:

The test results provide answers to the following questions:

View AntePC sample report

What is my genetic risk level of prostate cancer?
At what age should I start prostate cancer screening?
Should I take additional measures to prevent prostate cancer?
What can I do to reduce my risk of prostate cancer?
What changes and symptoms do I need to look out for regarding prostate cancer?

Changing people's lives

Early detection makes a difference

3

Every 3rd man gets cancer during their lifetime.
1

Prostate cancer is the no 1 most common malignancy in men, accounting for 25% of all cancers. But in the early stages of the disease, prostate cancer can be successfully treated.
100%

The five-year survival rate for early prostate cancer patients is nearly 100%. But only about 30% of patients with advanced prostate cancer survive five years or longer.

Personalised cancer prevention is an up-to-date solution aimed at minimising the potential impact of three different cancers by tailoring it to your genetic risk level.

Tests take into account your unique characteristics – genetic composition, sex, age and ethnicity – which make your results fully personalised.

Personalised cancer prevention is meant for all men aged 40-70.

Research has shown that the genetic predisposition of many cancers is due to variants in many genes, meaning it is polygenic. Antegenes assesses a person’s risk of developing cancer using polygenic risk score technology, which is developed based on extensive international research. The polygenic risk score (PRS) sums up information over hundreds to thousands of genetic variants in the human genome. By combining the PRS with a person’s background (origin, age and gender), we are able to calculate a person’s risk of developing cancer and provide medical advice on prevention and early detection.

Based on the test results, you will receive personalised preventive recommendations from leading medical experts in the field. This guidance includes when and how to initiate cancer screening and other effective strategies to reduce your risks.

Armed with scientifically backed and well-documented medical advice, you are equipped to take preventive measures within your local healthcare system to proactively protect your health.

Approved by doctors and customers

Over 16 000 tests taken

"As a result of the Antegenes genetic test, I know that my risk of prostate cancer is elevated, and the test report provided solid medical guidance on how to routinely check my health. This knowledge gave me the conviction that I have to check my health earlier and regularly. Before any complaints appear."

Andres, 46
"For me, the greatest value is the information that I need to undergo cancer screening much earlier than the national plan suggests. The body awareness instructions provided by Antegenes are clear and easy to understand, helping me to transform my daily habits. I now also know which signs and changes I need to pay attention to."

Olar, 43

We’re here to answer your questions

What does AntePC test include?

Personalised prostate cancer prevention is based on the AntePC test, which includes genetic risk testing for prostate cancer.
AntePC Test Limitations
- AntePC test is not used to diagnose prostate cancer.
- An elevated risk estimated by the AntePC test does not mean that you will develop prostate cancer during your lifetime. Also, a moderate or lower risk does not mean that the probability of developing the diseases is zero.
- AntePC test does not assess the risk of your family and relatives, i.e. polygenic risk score-based disease risks may not be transmitted directly from parents to children
- AntePC test does not analyze rare pathogenic mutations in genes that significantly increase the risk of prostate cancer, such as BRCA1, BRCA2, ATM, CHEK2, EPCAM, HOXB13, MLH1, MSH2, MSH6 and others.
- The AntePC test is based on the most up-to-date scientific data, which may, however, be supplemented and changed in the future as additional information becomes available. The field of genetics is constantly evolving, which may lead to changes in risk assessments over time, as well as changes in test selection recommendations and clinical recommendations based on test results.
- Different polygenic risk scores predicting risks of the same trait may give different estimates of the individual’s risks due to differences in the genetic variants included in the models and their weights.
- The results of this test should be applied in context with other relevant clinical data. In addition to the possible genetic predisposition, other risk factors also influence the risk of prostate cancer.

How it works?

1 Choose your tests
Select from our range of specialized tests tailored to your health and wellness needs.
2 Prepare for sampling
Receive easy-to-follow instructions for a convenient sample collection process in the comfort of your own home.
3 Provide a sample
Use the provided kit to collect a sample, following guidelines to capture the genetic information needed for testing.
4 Receive your results
Receive results quickly, accompanied by recommendations and guidance for your next steps.